Blog
12 Things I’m Grateful For Because of Vasculitis
- General Vasculitis
Blog ‘Tis the season of thankfulness. Although life with vasculitis isn’t always easy, we wanted to know: how has this disease impacted you for the better? We reached out to our community and asked them: “Despite vasculitis, or because of it, what are you grateful for?” Here’s what some of you said: Without vasculitis, I […]
Amgen Successfully Completes Acquisition of ChemoCentryx
- News, Pharmaceutical, Treatment
- General Vasculitis
Blog TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) – Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders […]
US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica
- News, Pharmaceutical, Treatment
- Polymyalgia Rheumatica
Blog The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adult patients. Kevzara has been approved as the first and only biologic indicated for PMR adult patients who did not respond to corticosteroids or who cannot tolerate corticosteroid taper. Developed using […]
“We Need Each Other” – The Nourishing Power of Friendship in the Vasculitis Community
- Support Group
- General Vasculitis, Giant Cell Arteritis
Blog Suzanne McLaughlin sat, mostly quiet, as others in that week’s Vasculitis Foundation support group took turns sharing their updates and stories. She kept her unassuming presence until the group neared its close and Dana, the facilitator, said, “Suzanne, I love how you listen intently during groups and take notes. And then you drop your […]
Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA)
- News, Pharmaceutical
- Eosinophilic Granulomatosis with Polyangiitis
Blog First head-to-head trial of biologics in EGPA, comparing a single monthly injection of Fasenra to three injections per month of mepolizumab Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s Fasenra (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared to mepolizumab in patients with eosinophilic […]
The Right Doctor Changes Everything
- Story
- Cryoglobulinemic Vasculitis
Blog For five years, doctors told Stephanie there was nothing wrong with her. Her bloodwork was inconclusive. In her hospital records, doctors dismissed her as “psychosomatic.” But her pain and fatigue kept getting worse. At one point, she was bed-bound for seven months until one doctor, assuming her symptoms were auto-immune related, finally started her […]
